At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KLRA Kailera Therapeutics
Closed Juneteenth National Independence Day 06-18 16:00:00 EDT
19.90
+0.77
+4.03%
盘后19.90
+0.000.00%
19:12 EDT
High20.49Low19.21Vol4.36M
Open19.38D1 Closing19.13Amplitude6.69%
Mkt Cap2.58BTradable Cap893.95MTotal Shares129.54M
T/O86.56MT/O Rate9.70%Tradable Shares44.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks
THOMSON REUTERS  ·  06-06
Kailera Therapeutics - Phase 2 Ribupatide Oral Shows up to 12.1% Mean Weight Loss at 26 Weeks
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
GlobeNewswire  ·  06-06
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
GlobeNewswire  ·  05-29
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  05-28
Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)
TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  05-27
TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M
Benzinga  ·  05-27
Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M
Kailera Q1 FY26 net loss more than quadruples to $78.87 million
Reuters  ·  05-27
Kailera Q1 FY26 net loss more than quadruples to $78.87 million
Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln
THOMSON REUTERS  ·  05-27
Kailera Therapeutics Inc - Q1 Net Loss $78.9 Mln
Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials
THOMSON REUTERS  ·  05-27
Kailera Therapeutics Inc - Reports Positive Topline Data From Phase 3 Hrs-7535 and Phase 1 Hrs-4729 Trials
Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028
THOMSON REUTERS  ·  05-27
Kailera Therapeutics Inc - Cash on Hand Expected to Fund Operations Into Mid-2028
Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Dow Jones  ·  05-27
Press Release: Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen
TIPRANKS  ·  05-22
Kailera Therapeutics, Inc. (KLRA) Receives a Buy from TD Cowen
Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)
TIPRANKS  ·  05-18
Analysts Offer Insights on NA Companies: Arxis, Inc. Class A (ARXS) and Kailera Therapeutics, Inc. (KLRA)
ADVISORY-Research alert on Kailera Therapeutics withdrawn
Reuters  ·  05-14
ADVISORY-Research alert on Kailera Therapeutics withdrawn
Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57
THOMSON REUTERS  ·  05-14
Kailera Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Price Target $57
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Benzinga  ·  05-14
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA
Reuters  ·  05-13
Kailera presents Phase 1 ribupatide injection data supporting global Phase 3 KaiNETIC program at ADA
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
GlobeNewswire  ·  05-13
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
Kailera Therapeutics initiated with an Outperform at Evercore ISI
TIPRANKS  ·  05-12
Kailera Therapeutics initiated with an Outperform at Evercore ISI
Kailera Therapeutics Initiated at Outperform by Evercore ISI Group
Dow Jones  ·  05-12
Kailera Therapeutics Initiated at Outperform by Evercore ISI Group

Introduction

Company Name.
Kailera Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--